QQQ   293.86 (+0.17%)
AAPL   148.62 (+0.40%)
MSFT   255.51 (+0.15%)
META   120.30 (+1.86%)
GOOGL   101.20 (+0.21%)
AMZN   95.50 (-1.08%)
TSLA   194.27 (-0.22%)
NVDA   171.83 (+1.54%)
NIO   12.09 (-5.40%)
BABA   86.19 (-1.56%)
AMD   77.28 (-0.45%)
T   19.16 (-0.62%)
MU   55.58 (-3.59%)
CGC   3.87 (+6.91%)
F   14.05 (+1.08%)
GE   85.39 (-0.67%)
DIS   98.34 (+0.48%)
AMC   8.64 (+19.50%)
PYPL   78.26 (-0.19%)
PFE   51.04 (+1.82%)
NFLX   317.67 (+3.97%)
QQQ   293.86 (+0.17%)
AAPL   148.62 (+0.40%)
MSFT   255.51 (+0.15%)
META   120.30 (+1.86%)
GOOGL   101.20 (+0.21%)
AMZN   95.50 (-1.08%)
TSLA   194.27 (-0.22%)
NVDA   171.83 (+1.54%)
NIO   12.09 (-5.40%)
BABA   86.19 (-1.56%)
AMD   77.28 (-0.45%)
T   19.16 (-0.62%)
MU   55.58 (-3.59%)
CGC   3.87 (+6.91%)
F   14.05 (+1.08%)
GE   85.39 (-0.67%)
DIS   98.34 (+0.48%)
AMC   8.64 (+19.50%)
PYPL   78.26 (-0.19%)
PFE   51.04 (+1.82%)
NFLX   317.67 (+3.97%)
QQQ   293.86 (+0.17%)
AAPL   148.62 (+0.40%)
MSFT   255.51 (+0.15%)
META   120.30 (+1.86%)
GOOGL   101.20 (+0.21%)
AMZN   95.50 (-1.08%)
TSLA   194.27 (-0.22%)
NVDA   171.83 (+1.54%)
NIO   12.09 (-5.40%)
BABA   86.19 (-1.56%)
AMD   77.28 (-0.45%)
T   19.16 (-0.62%)
MU   55.58 (-3.59%)
CGC   3.87 (+6.91%)
F   14.05 (+1.08%)
GE   85.39 (-0.67%)
DIS   98.34 (+0.48%)
AMC   8.64 (+19.50%)
PYPL   78.26 (-0.19%)
PFE   51.04 (+1.82%)
NFLX   317.67 (+3.97%)
QQQ   293.86 (+0.17%)
AAPL   148.62 (+0.40%)
MSFT   255.51 (+0.15%)
META   120.30 (+1.86%)
GOOGL   101.20 (+0.21%)
AMZN   95.50 (-1.08%)
TSLA   194.27 (-0.22%)
NVDA   171.83 (+1.54%)
NIO   12.09 (-5.40%)
BABA   86.19 (-1.56%)
AMD   77.28 (-0.45%)
T   19.16 (-0.62%)
MU   55.58 (-3.59%)
CGC   3.87 (+6.91%)
F   14.05 (+1.08%)
GE   85.39 (-0.67%)
DIS   98.34 (+0.48%)
AMC   8.64 (+19.50%)
PYPL   78.26 (-0.19%)
PFE   51.04 (+1.82%)
NFLX   317.67 (+3.97%)
OTCMKTS:BIOVF

Swedish Orphan Biovitrum AB (publ) - BIOVF Price Target & Analyst Ratings

$21.15
+1.77 (+9.13%)
(As of 11/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$21.15
$21.15
50-Day Range
$18.25
$20.70
52-Week Range
$18.25
$24.99
Volume
100 shs
Average Volume
10,312 shs
Market Capitalization
$6.24 billion
P/E Ratio
23.50
Dividend Yield
N/A
Price Target
N/A

Swedish Orphan Biovitrum AB (publ) Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 4 Analyst Ratings

Consensus Analyst Price Target

N/A

TypeCurrent
12/1/21 to 12/1/22
1 Month Ago
11/1/21 to 11/1/22
3 Months Ago
9/2/21 to 9/2/22
1 Year Ago
12/1/20 to 12/1/21
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
1 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
6 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price TargetN/AN/AN/A$20.00
Predicted UpsideN/AN/AN/AN/A
Get Swedish Orphan Biovitrum AB (publ) Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BIOVF and its competitors with MarketBeat's FREE daily newsletter.


BIOVF Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BIOVF Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Swedish Orphan Biovitrum AB (publ) Stock vs. The Competition

TypeSwedish Orphan Biovitrum AB (publ)Medical CompaniesS&P 500
Consensus Rating Score
2.75
2.66
2.48
Consensus RatingModerate BuyBuyHold
Predicted Upside576.51% Upside11.46% Upside
News Sentiment RatingNeutral News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
17
38.64%
Underperform Votes
27
61.36%
Avg. Outperform Votes
164
66.40%
Avg. Underperform Votes
83
33.60%
Avg. Outperform Votes
853
68.13%
Avg. Underperform Votes
399
31.87%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/28/2022Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageSector Perform
8/1/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight
4/14/2022DNB Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
2/22/2022Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetSEK 210 ➝ SEK 215
2/11/2022Nordea Equity Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
10/27/2021Pareto Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
7/21/2021Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
5/5/2021SEB Equity Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
5/5/2021SEB Equities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
2/19/2021Danske
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
(Data available from 12/1/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












BIOVF Price Target - Frequently Asked Questions

What is Swedish Orphan Biovitrum AB (publ)'s consensus rating?

According to the issued ratings of 4 analysts in the last year, the consensus rating for Swedish Orphan Biovitrum AB (publ) stock is Moderate Buy based on the current 1 hold rating and 3 buy ratings for BIOVFthe . Learn more on BIOVF's analyst rating history.

Do Wall Street analysts like Swedish Orphan Biovitrum AB (publ) more than its competitors?

Analysts like Swedish Orphan Biovitrum AB (publ) more than other Medical companies. The consensus rating for Swedish Orphan Biovitrum AB (publ) is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how BIOVF compares to other companies.

Do MarketBeat users like Swedish Orphan Biovitrum AB (publ) more than its competitors?

MarketBeat users like Swedish Orphan Biovitrum AB (publ) less than other Medical companies. 38.64% of MarketBeat users gave Swedish Orphan Biovitrum AB (publ) an outperform vote while medical companies recieve an average of 66.40% outperform votes by MarketBeat users.

What analysts cover Swedish Orphan Biovitrum AB (publ)?

Swedish Orphan Biovitrum AB (publ) has been rated by Royal Bank of Canada in the past 90 days.


Stock Ratings Reports and Tools

This page (OTCMKTS:BIOVF) was last updated on 12/1/2022 by MarketBeat.com Staff